1pm on Tuesday 2nd August 2016 in Room 2105 Physical Sciences Building
Adaptive Redesign in Nanoscale Drug Delivery:
Overcoming the Obstacles from Chemotherapy to Genome Engineering
Prof. K. Swaminathan Iyer
ARC Future Fellow and Leader: UWA-BioNano Initiative
Deputy HoS, School of Chemistry and Biochemistry
The University of Western Australia
Abstract: The intelligent design of nanoformulations seek to expand upon the benefits of the first- generation, clinically tested delivery agents by adding functionalities intended to improve delivery, therapeutic efficacy, and ultimately patient outcome. Compared with delivering drugs or imaging agents alone, multimodal nanoformulations can simultaneously deliver imaging and therapeutic agents enabling detection and treatment of cancer in a single procedure. These agents are designed to help make informed decisions about timing, dosage, drug choice, and treatment strategies. However these delivery agents have to constantly evolve keeping in mind the enormous advances in the nature of the treatment modalities from small molecules to high precision genome engineering tools.
In this presentation, I will focus on the design and utility of a poly(glycidal methacrylate) [PGMA] based colloidal and dendritic nanoformulations both as a theranostic platforms and gene delivery agents for cancer therapy. I will highlight the necessity to incorporate an adaptive redesign strategy keeping in mind the type of cancer, delivery agents and the clinical relevance of the approach. Using four globally relevant cancer models (Brca2/p53- knockout breast cancer, Apc-deficient crypt progenitor colon cancer, castration-resistant prostate cancer and triple negative breast cancer), I will discus different modes of treatment (in-site injection, oral and intravenous administration) and most importantly the opportunities/challenges encountered by adopting this approach for treatment.